Merck's WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With Combined Post- and Precapillary Pulmonary Hypertension (CpcPH) due to Heart Failure With Preserved Ejection Fraction (HFpEF)

RAHWAY, N.J.--(BUSINESS WIRE)--Merck's WINREVAIRâ,,¢ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With CpcPH due to HFpEF. ...